SM Teo Chee Hean Explores Singapore’s Future in Cell and Gene Therapy at ACTRIS

We had the pleasure of hosting Mr Teo Chee Hean, Senior Minister and Coordinating Minister for National Security and Special Advisor to National Research Foundation Singapore, at our cell therapy facility.

Adj A/Prof Danny Soon, CRIS CEO and ACTRIS Interim Executive Director, provided an overview of ACTRIS’ integral role in supporting clinical trials and clinical services for cell and gene therapies by providing manufacturing and process development services for our healthcare, research and biotech ecosystem.

Dr Andre Choo, Deputy Executive Director, A*STAR Bioprocessing Technology Institute (BTI), and colleagues then provided an update on Singapore’s recent developments in R&D and biotech initiatives for CGT. By harnessing innovative manufacturing technologies and establishing strategic partnerships we are advancing forward in translating cutting-edge research into effective CGTs for better patient outcomes.

Following this, SM Teo engaged in a meaningful discussion with the team on how Singapore can facilitate more public-private partnerships with companies looking to develop their CGT products in Singapore. The conversation also touched on strategies for enhancing capabilities to meet the growing demand for cell therapy development and manufacturing for cancer treatments and regenerative medicine, so that Singapore can continue to be relevant in this fast-evolving biomedical field.

To culminate the visit, SM Teo toured the translational laboratories for a deeper understanding of the manufacturing process of at the facility for patients’ access in our local hospitals.

It was an insightful afternoon of knowledge exchange with strategic partners. We are excited about the possibilities that lie ahead as we continue to explore synergies and push the boundaries of cell therapy together.

You may view our LinkedIn post here.